Discover and read the best of Twitter Threads about #HTN
Most recents (10)
1) Welcome to our #accredited #tweetorial on clinical trial results and emerging data for treatment of Diabetes and CKD #DM in #CKD. I am Brian Rifkin MD, @brian_rifkin, from the Hattiesburg Clinic. #Nephtwitter #Medtwitter #FOAMed 
2) This #accredited #tweetorial series on #kidneydisease #CKD is supported by an independent educational grant from the Boehringer Ingelheim/Lilly Alliance. It is not intended for US- or UK-based HCPs. Accreditation statement & faculty disclosures at ckd-ce.com/disclosures/.
3) This activity is accredited for #physicians #physicianassociates #nurses #NPs #pharmacists. Prior programs in this series, still eligible for CE/#CME, can be accessed at ckd-ce.com. FOLLOW US to learn from expert faculty!
1) Welcome to this new #accredited #tweetorial on “Strategies to Apply Current Clinical Trial Data for SGLT2i to Reduce the Progression of CKD,” authored by our ⭐️tweetorialist Edgar V. Lerma 🇵🇭 @edgarvlermamd
2) This program is #accredited for CE/#CME #physicians #physicianassociates #nurses #pharmacists #nursepractitioners & is supported by an educational grant from the Boehringer Ingelheim Pharmaceuticals Inc and Eli Lilly Company. It is intended for healthcare professionals.
3) Faculty disclosures and statement of accreditation are provided at ckd-ce.com/disclosures/. Please FOLLOW @ckd_ce (& @cardiomet_CE!) so you don't miss ANY of our unique serialized #tweetorials, always 🆓, always from expert authors! Prior programs at ckd-ce.com/category/dkd/ .
🧵 Reducing #PrescribingCascades ⬇️
1/ What are #Prescribing Cascades?
1⃣ A drug is prescribed 💊
2⃣ #AdverseEvent occurs but is misinterpreted as a new medical condition ⚠️
3⃣Another drug is prescribed for the drug-induced adverse event 💊💊
ti.ubc.ca/letter138 #MedEd
1/ What are #Prescribing Cascades?
1⃣ A drug is prescribed 💊
2⃣ #AdverseEvent occurs but is misinterpreted as a new medical condition ⚠️
3⃣Another drug is prescribed for the drug-induced adverse event 💊💊
ti.ubc.ca/letter138 #MedEd
2/ Anticholinergics ➡️ cognitive dysfunction ➡️ drugs for #dementia
#Anticholinergic 💊 block acetylcholinergic neurotransmission in the brain, impairing cognition & memory
Can lead to new Rx or ↗️ acetylcholinesterase inhibitor doses
ti.ubc.ca/letter138 #MedEd #FOAMed
#Anticholinergic 💊 block acetylcholinergic neurotransmission in the brain, impairing cognition & memory
Can lead to new Rx or ↗️ acetylcholinesterase inhibitor doses
ti.ubc.ca/letter138 #MedEd #FOAMed
3/ Drugs for #dementia ➡️ incontinence ➡️ anticholinergics
Conversely, AChE-I can cause urinary or fecal incontinence, that may "cascade" to prescription of an #anticholinergic
👉🏽 full Letter here: ti.ubc.ca/letter138
#MedEd #PrescribingCascades #MedTwitter
Conversely, AChE-I can cause urinary or fecal incontinence, that may "cascade" to prescription of an #anticholinergic
👉🏽 full Letter here: ti.ubc.ca/letter138
#MedEd #PrescribingCascades #MedTwitter
1) Welcome to a #tweetorial on what every #ICU #nurse should know about #hypertensive crisis, or #hypertensive #emergency as it is now more properly termed. I’m Bryan Boling @bryanboling, ICU #NP, & co-host of the @icuscenarios podcast. Follow this 🧵for 🆓CE/#CME credit!
2) This accredited educational activity is intended for healthcare providers & is supported by grants from AstraZeneca, Bayer, & Chiesi. Faculty disclosures cardiometabolic-ce.com/disclosures/. Like ❤️this topic? More CE/#CME on #hypertension mgt at cardiometabolic-ce.com/category/hyper….
3) So let's start with a case: 65yo ♂️, presents to the #ED with #headache, lethargy & confusion. PMH: #HTN, #hyperlipidemia, #DM2, COPD. Initial VS: HR 85, BP 205/120, T 37.2 RR 12, SpO2 92% on RA. Family reports that he has been more lethargic over the past 2 days.
1) Welcome to our new #accredited #tweetorial on #mechanismofaction & impact of meds commonly used in patients with or at risk for #DKD progression: #MRAs, #GLP-1 receptor agonists & #DPP-4 inhibitors. I am Sophia Ambruso DO, @sophia_kidney, from @CU_Kidney.
2) This #accredited #tweetorial series on #kidneydisease #DKD through the lens of #T2D is supported by an independent educational grant from the Boehringer Ingelheim/Lilly Alliance and is intended for healthcare providers.
3) This activity is accredited for #physicians #physicianassociates #nurses #NPs #pharmacists. Past programs still eligible for credit can be found at ckd-ce.com. Faculty disclosures are at ckd-ce.com/disclosures/. FOLLOW US for regular programs by expert faculty!
🔥Off the press: focused review on #race #ethnicity #hypertension #heartdisease w @KcfMd @ycommodore @JACCJournals #healthequity #bloodpressure #HTNroundtable #HTN80 #CardioTwitter #medtwitter @HHSGov @Surgeon_General @HeartNews @ABCardio1 @ACCinTouch
bit.ly/3rTMDG4
bit.ly/3rTMDG4
🩺#hypertension is the leading preventable #riskfactor for #heartdisease & #stroke
🩺#hypertension is a major contributor to #racial & #ethnic #disparities in #cardiovasculardisease
🩺#hypertension rates among #Black adults are one of the highest rates of globally
#HTNroundtable
🩺#hypertension is a major contributor to #racial & #ethnic #disparities in #cardiovasculardisease
🩺#hypertension rates among #Black adults are one of the highest rates of globally
#HTNroundtable
🩺#hypertension #control remains a persistent #clinical problem & #publichealth #challenge
🩺We must eliminate these #disparities in #HTN and address #barriers to #hypertensioncontrol
🩺#HTN80 #HTNroundtable #HealthEquity #bloodpressure #hypertensioncontrol
🩺We must eliminate these #disparities in #HTN and address #barriers to #hypertensioncontrol
🩺#HTN80 #HTNroundtable #HealthEquity #bloodpressure #hypertensioncontrol
World class @ClevelandClinic Hospital Medicine Grand Rounds - Update in #HospitalMedicine by Dr. Jessica Donato! A rising star! @BIDMC_IM @HarvardHospMed @CWRUSOM @SocietyHospMed
Is postop #afib associated w increased risk for CVA/TIA?
2/8 However, our study was unique in design compared w/ prior studies, allowing for more accurate estimates of mortality risk: 1) larger, more representative cohort; 2) more contemporary control groups
3/8 We characterized mortality risk separately for pts with pre-hospital and in-hospital #STEMI
Resistant Hypertension in CKD, How i treat?
===========================
Teaching points from this article are the following thread.
#NephTwitter #CKD #Hypertension #HTN
===========================
Teaching points from this article are the following thread.
#NephTwitter #CKD #Hypertension #HTN
👉Full link for the article: cjasn.asnjournals.org/content/16/3/4…
👉Apparent resistant hypertension is common in CKD.
👉Assessment for pseudoresistance, including out of office BP monitoring, should be done.
👉Nonpharmacologic measures should be reinforced, along with optimizing pharmacologic therapy.
👉Assessment for pseudoresistance, including out of office BP monitoring, should be done.
👉Nonpharmacologic measures should be reinforced, along with optimizing pharmacologic therapy.
1/4 Brief reading break from COVID tweets?
Happy to share new #HTN work in @JAMAInternalMed examining the representativeness of trials underlying 2017 BP guidelines
Takeaway:<1/3 of adults rec'd additional BP meds by guidelines meet trial eligibility
ja.ma/38R5tk5
Happy to share new #HTN work in @JAMAInternalMed examining the representativeness of trials underlying 2017 BP guidelines
Takeaway:<1/3 of adults rec'd additional BP meds by guidelines meet trial eligibility
ja.ma/38R5tk5
2/4 Trials most representative of adults 50-69.
Younger adults not included in trials due to low CV risk - benefit of early intensive BP treatment remains unknown
Older adults often excluded due to comorbidities, limited life expectancy, & impaired cognition.
Younger adults not included in trials due to low CV risk - benefit of early intensive BP treatment remains unknown
Older adults often excluded due to comorbidities, limited life expectancy, & impaired cognition.
3/4 As a PCP, I think a lot about how pop health initiatives anchor us on numeric targets...
Given these evidence gaps, tailoring of BP treatment recs by degree of BP elevation, competing risks, and time to benefit is likely preferable to unwavering adoption of strict targets
Given these evidence gaps, tailoring of BP treatment recs by degree of BP elevation, competing risks, and time to benefit is likely preferable to unwavering adoption of strict targets
